Bearish
Stifel cut its price target on Boston Scientific Corporation (NYSE:BSX) to $65 from $75, while reaffirming a Buy rating, citing factors like negative ...
Neutral
ABN AMRO Bank N.V. lowered its stake in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) by 23.5% during the 1st quarter, according to...
Neutral
Jefferies maintained a Buy rating for Boston Scientific (BSX) but lowered the price target from $100.00 to $67.00. Despite this adjustment, GuruFocus ...
Neutral
Piper Sandler has maintained an Overweight rating for Boston Scientific (BSX) despite reducing its target price from $90 to $65, citing a slowdown in ...
Neutral
SG Americas Securities LLC lifted its stake in Boston Scientific Corporation (NYSE:BSX – Free Report) by 140.9% during the first quarter, Holdings Cha...
Neutral
Boston Scientific Corp. failed to convince the Federal Circuit to block the launch of Stryker Corp.'s OptaBlate BVN product, a surgical device used to...
Neutral
Truist has reiterated a Buy rating for Boston Scientific (BSX) despite lowering its price target from $85 to $64 due to slowed growth of the Watchman ...
Bullish
Penumbra has received FDA clearance for its Thunderbolt computer-assisted vacuum thrombectomy device, designed for clot removal in stroke patients. Th...
Neutral
UniSuper Management Pty Ltd significantly reduced its stake in Boston Scientific Corporation by 29.5% in the fourth quarter, selling 318,658 shares an...
Neutral
Boston Scientific's stock has dropped to a 52-week low of $47.16, marking a 51% decline over the past year and 47% in the last six months. Despite thi...
Neutral
Boston Scientific (BSX) has experienced a significant de-rating in 2026, with share prices down nearly 50%, despite most analysts maintaining bullish ...
Neutral
Boston Scientific (BSX) is identified as one of the best healthcare stocks with high upside potential, despite recent price target cuts by TD Cowen an...
Bearish
Truist Securities has lowered its price target for Boston Scientific Corp. (NYSE:BSX) to $64 from $85, while maintaining a Buy rating, due to a slowdo...
Bullish
Boston Scientific is investing $1.5 billion in MiRus, a Marietta-based heart-valve startup, a year after exiting the heart valve replacement market. T...